Catch It Early
l@sasacul123
0.0%
since Oct 8
The idea
I believe early detection is about to become routine medicine, so this take owns the whole chain. Cancer blood tests are the biggest piece, led by GRAIL with its pending FDA decision, alongside other test makers. The steadier half owns the labs, instrument makers, and imaging companies that profit no matter which test wins, plus names tied to Alzheimer's and heart detection. No single holding dominates, a slice stays in cash, and the idea is built to hold for years as coverage and approvals unfold.
What it owns
- Blood tests that detect cancer early are entering widespread use, creating a new screening category that reaches millions of people. · GRAIL, Inc.Its multi-cancer blood test passed a strong FDA advisory panel vote, positioning it as a potential standard screening tool if approved., Guardant HealthIts colon cancer blood test offers a simple screening option that competes with existing methods and gains adoption among patients and insurers., NateraIts blood test detects cancer recurrence early and is becoming standard in oncology protocols and clinical trials., Abbott LaboratoriesThrough its acquisition of the Cologuard at-home screening business, it now owns one of the largest colorectal cancer testing platforms., Tempus AIIt runs genetic tests and AI analysis on large patient datasets to enable earlier disease detection across cancer and heart conditions.33%
- Clinical labs and sequencing machines process every blood sample from new screening tests, so testing volume growth flows directly to these infrastructure providers. · LabcorpAs a major clinical lab, it processes samples from all screening tests and also offers the new Alzheimer's blood test through its network., Quest DiagnosticsIt draws blood for millions of Americans and profits from whichever screening tests doctors order, plus it offers the Alzheimer's test., IlluminaIts gene sequencing machines power many cancer blood tests, so wider adoption of screening drives demand for its instruments and reagents., DanaherIt supplies the lab instruments and systems that diagnostic centers use daily, providing steady exposure to growth in testing volume.24%
- Positive screening results send patients for confirmation scans, making imaging centers and scanner makers beneficiaries of expanded early detection. · RadNetIts outpatient imaging centers perform the follow-up scans that confirm positive screening results and drive revenue as testing expands., GE HealthCareIt manufactures the CT, MRI and PET scanners used to confirm blood test findings across cancer, heart and brain diseases.13%
- New blood tests for Alzheimer's disease enable earlier diagnosis, which drives both test adoption and treatment starts among newly identified patients. · Eli LillyIts FDA-cleared Alzheimer's blood test drives earlier diagnosis, which expands the eligible population for its Alzheimer's drug., BiogenEasier Alzheimer's diagnosis through blood tests expands the patient pool who can be identified and started on its Leqembi treatment., QuanterixIt makes ultra-sensitive protein measurement tools used in many Alzheimer's blood tests, serving labs and drug companies developing these assays.12%
- Advanced monitoring and AI analysis of heart scans catch disease before symptoms appear, addressing the leading cause of death with earlier intervention. · HeartFlowIts AI reads heart scans to detect disease before symptoms, and expanding insurance coverage is growing its revenue rapidly., iRhythm TechnologiesIts heart rhythm patches catch irregular heartbeats that cause strokes, and its acquisition of hospital monitoring technology extends its reach.10%
- Cash8%